A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients
← catalyst calendarNCT03569553 · readout ≤ 346 d
Sponsored by Emergent BioSolutions (industry) · EBS — their whole pipeline →. With Centers for Disease Control and Prevention, Department of Health and Human Services.
Phase
—
Status
Not yet recruiting
Study type
Observational
Enrollment
100estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2027-05-30 | estimated | When the study began enrolling |
| Primary completion | Jul 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2018-06-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Inhalational Anthrax
Intervention
- Drug: AIGIV — also filed as ANTHRASIL®
Primary outcome
what the primary-completion date above is the date OFAssessment of AIGIV clinical benefit by overall mortality rate
measured Up to Day 30
Permalink · EBS's whole pipeline · Catalyst calendar · Every registered study · What changed